Print Friendly, PDF & Email

NCT/Study#

NCT02103478 /

ASTX727-01

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation And Dose-Confirmation Study Of ASTX727, A Combination Of The Oral Cytidine Deaminase Inhibitor (Cdai) E7727 With Oral Decitabine In Subjects With Myelodysplastic Syndromes (MDS)

DISEASE GROUP:
Leukemia
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: